Fountain, Daniel M 
ORCID: 0000-0001-6227-9930, Piper, Rory J ORCID: 0000-0002-6422-5853, Poon, Michael TC, Solomou, Georgios ORCID: 0000-0002-9795-0517, Brennan, Paul M ORCID: 0000-0002-7347-830X, Chowdhury, Yasir A, Colombo, Francesca ORCID: 0000-0002-2018-7779, Elmoslemany, Tarek ORCID: 0000-0003-3619-7581, Ewbank, Frederick G, Grundy, Paul L et al (show 21 more authors)
(2021)
CovidNeuroOnc: A UK multicenter, prospective cohort study of the impact of the COVID-19 pandemic on the neuro-oncology service.
Neuro-oncology advances, 3 (1).
vdab014-.
ISSN 2632-2498, 2632-2498
|
Text
CovidNeuroOnc A UK multicenter, prospective cohort study of the impact of the COVID-19 pandemic on the neuro-oncology servic.pdf - Published version Download (496kB) | Preview |
Abstract
<h4>Background</h4>The COVID-19 pandemic has profoundly affected cancer services. Our objective was to determine the effect of the COVID-19 pandemic on decision making and the resulting outcomes for patients with newly diagnosed or recurrent intracranial tumors.<h4>Methods</h4>We performed a multicenter prospective study of all adult patients discussed in weekly neuro-oncology and skull base multidisciplinary team meetings who had a newly diagnosed or recurrent intracranial (excluding pituitary) tumor between 01 April and 31 May 2020. All patients had at least 30-day follow-up data. Descriptive statistical reporting was used.<h4>Results</h4>There were 1357 referrals for newly diagnosed or recurrent intracranial tumors across 15 neuro-oncology centers. Of centers with all intracranial tumors, a change in initial management was reported in 8.6% of cases (<i>n</i> = 104/1210). Decisions to change the management plan reduced over time from a peak of 19% referrals at the start of the study to 0% by the end of the study period. Changes in management were reported in 16% (<i>n</i> = 75/466) of cases previously recommended for surgery and 28% of cases previously recommended for chemotherapy (<i>n</i> = 20/72). The reported SARS-CoV-2 infection rate was similar in surgical and non-surgical patients (2.6% vs. 2.4%, <i>P</i> > .9).<h4>Conclusions</h4>Disruption to neuro-oncology services in the UK caused by the COVID-19 pandemic was most marked in the first month, affecting all diagnoses. Patients considered for chemotherapy were most affected. In those recommended surgical treatment this was successfully completed. Longer-term outcome data will evaluate oncological treatments received by these patients and overall survival.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | British Neurosurgical Trainee Research Collaborative (BNTRC) |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 09 Jun 2021 08:58 |
| Last Modified: | 07 Dec 2024 22:44 |
| DOI: | 10.1093/noajnl/vdab014 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3125625 |
Altmetric
Altmetric
